ABSTRACT
Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question remains: Is this breakthrough combination therapy the "magic-bullet" cure for the vast majority of patients with CF? This review covers the contemporary clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights the emerging issues from recent conflicting literature reports.
Subject(s)
Aminophenols/therapeutic use , Aminopyridines/therapeutic use , Benzodioxoles/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/drug therapy , Quinolones/therapeutic use , Aminophenols/pharmacology , Aminopyridines/pharmacology , Benzodioxoles/pharmacology , Cystic Fibrosis/genetics , Cystic Fibrosis/physiopathology , Drug Approval , Drug Combinations , Humans , Quinolones/pharmacology , United States , United States Food and Drug AdministrationABSTRACT
Some degree of pain is a part of every individual's life. Many people, however, live in chronic debilitating pain. This Article examines concepts of pain and its treatment and implications for victims of pain under the Social Security system. The Article discusses inconsistencies within the Social Security Administration and in the courts when attempting to set standards for evaluating pain and determining disability.
Subject(s)
Disabled Persons/legislation & jurisprudence , Eligibility Determination/legislation & jurisprudence , Pain, Intractable/economics , Social Security/legislation & jurisprudence , Disability Evaluation , Humans , Insurance Benefits/legislation & jurisprudence , Pain, Intractable/classification , Social Security/standards , United States , United States Social Security Administration , Workers' Compensation/legislation & jurisprudenceABSTRACT
After explanation of the causes, symptomatology, diagnostics, and therapy of the intraperitoneal vesical rupture two cases are demonstrated which only four or five days, respectively, after the accident were diagnosed and underwent treatment. In one case it was the encapsulation of the urine extravasate by a fibrinous pseudomembrane in the abdominal cavity, in the other case a prolapsed into the vesical lumen intestinal loop which favoured a retarded course of the disease. Despite the demonstration of these two cases the demand of a quick diagnostics and operative therapy is preserved in all urgency, also in only clinical suspicion of an intraperitoneal vesical rupture.
